SOUL trial: Oral semaglutide demonstrates a 14% reduction in risk of major adverse CV events
Headline results from the SOUL cardiovascular outcomes trial show the trial achieved its primary objective by demonstrating a...
top of page
Browse by category
Search
Semaglutide cardiovascular benefits are maintained in people with impaired kidney function
Semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults...
Browse by tag
bottom of page